Share

    


In This Section

Home / News & Media / Educational Resources

Educational Resources

These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email CorporateRelations@accc-cancer.org for assistance.

  • Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

    Posted on 05/14/2025

     

    Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

    View Resource



  • A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

    Posted on 05/14/2025

     

    Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.



    Learn More



  • This Is Living With Cancerâ„¢

    Posted on 04/24/2025

    This Is Living With Cancerâ„¢ is a free online resource developed by Pfizer Oncology for all people living with cancer, regardless of age, income, race, location, cancer type, or stage of disease. This comprehensive program is available to anyone in the United States, whether they're on a Pfizer treatment or not, with a growing focus on those facing challenges accessing care.

    Direct your patients to ThisIsLivingWithCancer.com to learn more.

    View Resource



  • AMTAGVI Patient Identification and Referral Process

    Posted on 3/6/2025

    The only FDA-approved T cell therapy for previously treated advanced melanoma

    Geron-200x80

     

    View Resource



  • Does the Menin Pathway Play a Role in Your Patient’s AML?

    Posted on 2/18/2025

    Geron-200x80

     

    Visit Website



  • Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

    Published on: February 17, 2025

    Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

    View Resource Here




  • Centers for Medicare & Medicaid Services has assigned a permanent J-code for RYTELO

    Posted on 1/16/2025

    Geron-200x80

     

    Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.
    View Resource



  • Genentech-Pro: Product, Access, and Disease State Resources for Providers & Patients

    Posted on 12/28/2024

    Genentech-305x80

     

    View Resource



  • Patient Education on Medicare Prescription Payment Plan

    Posted on 12/02/2024

    Bayer-Global-80x80





    HCP’s: Use these handouts to help patients understand their Medicare plan:
    English Version   Spanish Version



  • Desmoid Tumor ICD-10-CM Codes Flashcard

    Posted on 11/20/2024

    SpringWorks-275x80





    FDA-Approved Therapy and ICD-10-CM Codes for Desmoid Tumors. Desmoid tumors are rare, locally aggressive soft tissue tumors that are characterized by high rates of initial misdiagnosis.
    View Resource